{
    "RADCURE-3397": {
        "question": "Age: 40.2, Sex: Male, ECOG PS: ECOG 1, Smoking PY: 5, Smoking Status: Ex-smoker, Ds Site: Nasopharynx, Subsite: Post wall, T: T3, N: N2, M : M0, Stage: III, Path: Neuroendocrine ca (small cell), HPV: positive, Tx Modality: ChemoRT, Chemo? : Yes, Dose: 70.0, Fx: 35, Local: none, Regional: none, Distant: none, 2nd Ca: none, ContrastEnhanced: 1\nAnswer: ",
        "recruit-recruiter": "1. Medical Oncologist - Your expertise is strictly limited to systemic therapy decisions, including chemotherapy and immunotherapy in neuroendocrine carcinomas of the nasopharynx, with consideration of HPV status and smoking history. - Hierarchy: Medical Oncologist",
        "initial_assessment-medical oncologist": "The provided bounding box coordinates [[249, 180, 114, 249, 204, 142], [249, 180, 114, 249, 204, 142]] indicate a very small volumetric region within the CT scan, specifically at a single slice (z=249) and a limited area in the y and x dimensions.\n\nFrom a medical oncologist's perspective focusing on neuroendocrine carcinoma of the nasopharynx:\n\n- The region corresponds anatomically to the nasopharyngeal area, likely including soft tissue structures posterior to the nasal cavity.\n- No obvious large mass or gross anatomical distortion is visible within this small ROI on the provided sagittal CT slice.\n- There is no clear evidence of bone erosion or invasion into adjacent critical structures such as the skull base or cervical spine in this limited view.\n- No obvious lymphadenopathy or distant metastatic lesions are visible in this region.\n- The absence of visible gross tumor or abnormality in this ROI may suggest either a small tumor burden or post-treatment changes if this is a follow-up scan.\n\nGiven the limited data and the small ROI, no definitive anatomical abnormality or tumor mass can be confidently identified here.\n\nFrom an oncologic standpoint, survival probability in nasopharyngeal neuroendocrine carcinoma depends heavily on tumor stage, nodal involvement, HPV status, smoking history, and treatment modality. Without visible gross disease in this ROI, if this corresponds to post-treatment imaging, it may indicate a favorable response.\n\nAnswer: Alive",
        "initial_assessment_review_assessment-medical oncologist": "Answer:Alive",
        "Round 1-role-comment": "medical oncologist:alive",
        "Round 1-num_agents": 1,
        "Round 2-Turn 1-discuss-participate_review_assessment-medical oncologist": "Answer:no",
        "Round 2-Turn 1-ask_gap_review_assessment-medical oncologist": "---\nAnswer: no\nReason: team scope covers required expertise\n---",
        "Round 2-role-comment": "medical oncologist:alive",
        "Round 2-num_agents": 1,
        "num_cooperations-panel": 0,
        "decision-Moderator": "('Answer: Alive',)"
    }
}